The cash flow of 10x Genomics, Inc. over the past 9 years
Chart 10x Genomics, Inc.: operating cash flow, capital expenditures, free cash flow, fiscal 2017–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, 10x Genomics, Inc.'s operating cash flow was $136.05M and its capital expenditures $5.93M, leaving free cash flow of $130.12M. Free cash flow was above zero in 1 of the 9 years shown. It ranged from -$254.56M in fiscal 2020 to $130.12M in fiscal 2025. Capital expenditures were highest in fiscal 2022, at $131.66M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $136.05M | $5.93M | $130.12M |
| 2024ended Dec 31, 2024 | $6.66M | $12.39M | -$5.73M |
| 2023ended Dec 31, 2023 | -$15.2M | $48.6M | -$63.8M |
| 2022ended Dec 31, 2022 | -$33.61M | $131.66M | -$165.27M |
| 2021ended Dec 31, 2021 | -$21.37M | $101.28M | -$122.65M |
| 2020ended Dec 31, 2020 | -$217.9M | $36.67M | -$254.56M |
| 2019ended Dec 31, 2019 | $34.63M | $42.74M | -$8.12M |
| 2018ended Dec 31, 2018 | -$76.41M | $6.28M | -$82.69M |
| 2017ended Dec 31, 2017 | -$10.7M | $3.76M | -$14.46M |
Fiscal years as 10x Genomics, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on 10x Genomics, Inc.
- The revenue of 10x Genomics, Inc.
- The profitability of 10x Genomics, Inc.
- The debt of 10x Genomics, Inc.
- All of 10x Genomics, Inc.'s financials, charted
Companies of a similar size
- HNGEHinge Health, Inc.
- DRSLeonardo DRS, Inc.
- HLHECLA MINING CO/DE/
- PBFPBF ENERGY INC.
- BAHBooz Allen Hamilton Holding Corporation
Not investment advice. This page shows what 10x Genomics, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.